Лечение артериальной гипертензии у больных с метаболическим синдром путем применения нифедипина (Кордафлекса РД)

Studied the effectiveness and safety of administration of the ex-tended-release calcium antagonist Nifedipin-Retard (Cordaflex-Retard, EGIS) in 30 patients with arterial hypertension of the 1st and 2nd degree. The study included general clinical examination, 24-hour ambulatory blood pressure monitoring. Cordaflex-Retard was administered depending on the initial BP, in the daily dose of 20 to 40 mg during 24 weeks. We found not only hypotensive action with the BP level stabilization, but also reduction of the magnitude and the rate of the SBP morning rise, as well as a greater degree of tile night dipping of the SBP and DBP.